The estimated Net Worth of Jane A Gross is at least $488 Tausend dollars as of 26 April 2023. Dr Gross owns over 6,000 units of Aptevo Therapeutics Inc stock worth over $2,166 and over the last 8 years he sold APVO stock worth over $0. In addition, he makes $485,680 as Sr. VP & Chief Scientific Officer at Aptevo Therapeutics Inc.
Sign up
Dr Gross APVO stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Aptevo Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of APVO stock worth $2,166 on 26 April 2023.
The largest trade he's ever made was exercising 6,000 units of Aptevo Therapeutics Inc stock on 26 April 2023 worth over $2,166. On average, Dr trades about 300 units every 0 days since 2017. As of 26 April 2023 he still owns at least 6,000 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Dr Gross stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Jane A. Gross biography
Dr. Jane A. Gross is the Sr. VP & Chief Scientific Officer at Aptevo Therapeutics Inc.
What is the salary of Dr Gross?
As the Sr. VP & Chief Scientific Officer of Aptevo Therapeutics Inc, the total compensation of Dr Gross at Aptevo Therapeutics Inc is $485,680. There are 2 executives at Aptevo Therapeutics Inc getting paid more, with Marvin L. White having the highest compensation of $859,495.
How old is Dr Gross?
Dr Gross is 63, he's been the Sr. VP & Chief Scientific Officer of Aptevo Therapeutics Inc since . There are no older and 2 younger executives at Aptevo Therapeutics Inc.
What's Dr Gross's mailing address?
Jane's mailing address filed with the SEC is C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121.
Insiders trading at Aptevo Therapeutics Inc
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri und Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
What does Aptevo Therapeutics Inc do?
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
What does Aptevo Therapeutics Inc's logo look like?
Complete history of Dr Gross stock trades at Aptevo Therapeutics Inc und Atyr Pharma Inc
Aptevo Therapeutics Inc executives and stock owners
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Marvin L. White,
Pres, CEO & Director -
Jeffrey G. Lamothe,
Sr. VP, CFO & Treasurer -
Dr. Jane A. Gross,
Sr. VP & Chief Scientific Officer -
Dr. Fatih M. Uckun M.D., Ph.D.,
Chief Clinical Advisor & Consultant -
SoYoung Kwon J.D., LL.M.,
Sr. VP, Gen. Counsel, Corp. Affairs & HR -
Censia Pottorf,
VP of HR -
Heather Boussios,
Acting Gen. Counsel & Assistant Sec. -
Stacey Jurchison,
Sr. Director of Investor Relations & Corp. Communications -
Scott C Stromatt,
Chief Medical Officer and SVP -
Fuad El Hibri,
Director -
Bio Solutions Inc. Emergent,
10% owner -
Daphne Taylor,
SVP, CFO -
Zsolt Harsanyi,
-
John Niederhuber,
-
Marvin L White,
President and CEO -
Daniel Abdun Nabi,
-
Grady Iii Grant,
-
Shawnte Mitchell,
SVP, GC and Corporate Affairs -
Michael Adelman,
SVP, Commercial Operations -
Jeffrey G. Lamothe,
EVP, COO -
Jane A Gross,
SVP & Chief Scientific Officer -
Randy Joe Maddux,
SVP of Operations, CMO -
Barbara Lopez Kunz,
-
So Young Kwon,
SVP, GC, BD & Corp Affairs -
Kevin Ctang Capital Managem...,